36 results on '"Kastelein, John J.P."'
Search Results
2. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
3. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study
4. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
5. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
6. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
7. Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study.
8. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
9. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
10. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
11. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
12. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
13. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia
14. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
15. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
16. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
17. Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
18. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
19. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
20. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
21. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation
22. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
23. Lipoprotein-associated phospholipase A 2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin
24. Corrigendum to “Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia” J Clin Lipidol 11 (2017) 1338-1346
25. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab versus placebo with heterozygous familial hypercholesterolemia
26. Management of Severe Hypertriglyceridemia with a Novel Omega-3 Free- Fatty Acid Formulation: Subgroups in the EVOLVE Trial
27. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin
28. 210
29. 206
30. 214
31. 407
32. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin.
33. 210: Safety and Efficacy of Atorvastatin at Very Low LDL-C Levels: A Post-Hoc Analysis of the Treating to New Targets (TNT) Study.
34. 206: A Comparison of the Association of On-Treatment Lipid and Apolipoprotein Parameters to Cardiovascular Events in IDEAL and TNT.
35. 407: Dose-dependent Reductions in LDL-C with ISIS 301012, an Antisense Inhibitor of Apolipoprotein B.
36. 214: Effect of Intensive Cholesterol Lowering With Atorvastatin in Patients with Previous Coronary Bypass Surgery: A Treating to New Targets (TNT) Substudy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.